Background: * The prevalence of arthritis which needs celecoxib prescription is high in patients with coronary artery disease. * The main concern is that celecoxib would increase thrombogenicity by inhibiting the synthesis of prostacyclin in endothelial cells. * It is not known whether the administration of celecoxib would deteriorate antiplatelet effects of aspirin and clopidogrel which are used after stenting. Methods: * Healthy volunteers (n=40) * Randomization into five subgroups * aspirin, celecoxib, aspirin+celecoxib, aspirin+clopidogrel, aspirin+clopidogrel+celecoxib * Medication schedule : medication of each drug for 6 days, blood samples at day 0 and day 7 * Celecoxib 200mg twice a day, and/or aspirin 100mg daily, and/or clopidogrel 75 mg daily * Platelet function test : light transmittance aggregometry and arachidonic acid metabolite assay among subgroups. Study hypothesis : The addition of celecoxib does not deteriorate antiplatelet function of aspirin and clopidogrel.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
aspirin 100 mg qd for 7 days
celecoxib 200 mg bid \* 7 days
aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
Seoul National University Hospital
Seoul, South Korea
Light transmittance aggregometry : % of inhibition (ADP, collagen)
Time frame: 7 days
Urine arachidonic metabolite assay
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.